These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19351540)

  • 1. Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD).
    Ueda S; Yamagishi S; Matsumoto Y; Kaida Y; Fujimi-Hayashida A; Koike K; Tanaka H; Fukami K; Okuda S
    Life Sci; 2009 Jun; 84(23-24):853-6. PubMed ID: 19351540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
    Matsumoto Y; Ueda S; Yamagishi S; Matsuguma K; Shibata R; Fukami K; Matsuoka H; Imaizumi T; Okuda S
    J Am Soc Nephrol; 2007 May; 18(5):1525-33. PubMed ID: 17409314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy.
    Shibata R; Ueda S; Yamagishi S; Kaida Y; Matsumoto Y; Fukami K; Hayashida A; Matsuoka H; Kato S; Kimoto M; Okuda S
    Nephrol Dial Transplant; 2009 Apr; 24(4):1162-9. PubMed ID: 19015171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
    Matsuguma K; Ueda S; Yamagishi S; Matsumoto Y; Kaneyuki U; Shibata R; Fujimura T; Matsuoka H; Kimoto M; Kato S; Imaizumi T; Okuda S
    J Am Soc Nephrol; 2006 Aug; 17(8):2176-83. PubMed ID: 16807406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of adipose tissue asymmetric dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in adipose tissue phenotype and metabolic abnormalities in subtotally nephrectomized rats.
    Minakuchi H; Wakino S; Hosoya K; Sueyasu K; Hasegawa K; Shinozuka K; Yoshifuji A; Futatsugi K; Komatsu M; Kanda T; Tokuyama H; Hayashi K; Itoh H
    Nephrol Dial Transplant; 2016 Mar; 31(3):413-23. PubMed ID: 26516203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.
    Wetzel MD; Gao T; Stanley K; Cooper TK; Morris SM; Awad AS
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F509-F517. PubMed ID: 31904280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Lowering of Asymmetric Dimethylarginine by Pharmacological Dimethylarginine Dimethylaminohydrolase Improves Endothelial Function, Reduces Blood Pressure and Ischemia-Reperfusion Injury.
    Lee Y; Mehrotra P; Basile D; Ullah M; Singh A; Skill N; Younes ST; Sasser J; Shekhar A; Singh J
    J Pharmacol Exp Ther; 2021 Feb; 376(2):181-189. PubMed ID: 33214214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
    Desai A; Zhao Y; Warren JS
    Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.
    Jiang DJ; Jia SJ; Yan J; Zhou Z; Yuan Q; Li YJ
    Biochem Biophys Res Commun; 2006 Oct; 349(2):683-93. PubMed ID: 16959216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
    Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
    Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension.
    Millatt LJ; Whitley GS; Li D; Leiper JM; Siragy HM; Carey RM; Johns RA
    Circulation; 2003 Sep; 108(12):1493-8. PubMed ID: 12952847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.
    Wakino S; Hayashi K; Tatematsu S; Hasegawa K; Takamatsu I; Kanda T; Homma K; Yoshioka K; Sugano N; Saruta T
    Hypertens Res; 2005 Mar; 28(3):255-62. PubMed ID: 16097370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.
    Mihout F; Shweke N; Bigé N; Jouanneau C; Dussaule JC; Ronco P; Chatziantoniou C; Boffa JJ
    J Pathol; 2011 Jan; 223(1):37-45. PubMed ID: 20845411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
    Baylis C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome.
    Kaida Y; Ueda S; Yamagishi S; Nakayama Y; Ando R; Iwatani R; Fukami K; Okuda S
    Life Sci; 2012 Sep; 91(9-10):301-5. PubMed ID: 22749861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
    Tatematsu S; Wakino S; Kanda T; Homma K; Yoshioka K; Hasegawa K; Sugano N; Kimoto M; Saruta T; Hayashi K
    J Am Soc Nephrol; 2007 Mar; 18(3):741-9. PubMed ID: 17267746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
    Selley ML
    J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia.
    Yokoro M; Nakayama Y; Yamagishi SI; Ando R; Sugiyama M; Ito S; Yano J; Taguchi K; Kaida Y; Saigusa D; Kimoto M; Abe T; Ueda S; Fukami K
    J Am Soc Nephrol; 2017 Sep; 28(9):2670-2680. PubMed ID: 28600471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.
    Feng M; Liu L; Guo Z; Xiong Y
    Eur J Pharmacol; 2008 Apr; 584(1):49-56. PubMed ID: 18342305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase.
    Scalera F; Kielstein JT; Martens-Lobenhoffer J; Postel SC; Täger M; Bode-Böger SM
    J Am Soc Nephrol; 2005 Apr; 16(4):892-8. PubMed ID: 15728783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.